Neutropenic enterocolitis: An unusual complication of HCV combination therapy with PEG-IFN and ribavirin

Eur J Intern Med. 2008 Jul;19(5):372-3. doi: 10.1016/j.ejim.2007.10.014. Epub 2007 Nov 26.

Abstract

Drug induced neutropenia as a consequence of intensive chemotherapy for hematological malignancies and solid tumors is known to be associated with severe, life-threatening infections such as neutropenic enterocolitis. However, the neutropenia associated with HCV combination therapy with Pegylated Interferon [PEG-IFN] and ribavirin is considered to be well tolerated in patients without other co-morbidities. We present a case of a severe gastrointestinal complication in a patient receiving HCV combination therapy and advocate caution in continuing therapy in patients with neutropenia, especially in the presence of underlying co-morbidities such as cirrhosis.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antiviral Agents
  • Drug Therapy, Combination
  • Enterocolitis, Neutropenic / chemically induced*
  • Enterocolitis, Neutropenic / diagnosis
  • Enterocolitis, Neutropenic / drug therapy
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Hepatitis C / drug therapy
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Male
  • Middle Aged
  • Polyethylene Glycols / adverse effects*
  • Recombinant Proteins
  • Ribavirin / adverse effects*
  • Tomography, X-Ray Computed

Substances

  • Anti-Bacterial Agents
  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Polyethylene Glycols
  • Ribavirin
  • Filgrastim
  • peginterferon alfa-2a